@文章{信息:doi/10.2196/26439，作者=“陈玉玲与吉，美华与吴，莹与王，青玉与邓，莹与刘，勇与吴，方琴与刘，明轩与郭，一强与傅，紫媛与郑晓莹”，标题=“冠心病个体风险消除智能个体化心血管App (iCARE):《开发与可用性测试分析》，期刊=“JMIR移动健康Uhealth”，年=“2021”，月=“12”，日=“13”，卷=“9”，号=“12”，页=“e26439”，关键词=“移动健康;健康行为;系统;发展;可用性;背景:改善危险因素管理可大大减少冠心病(CHD)的死亡和残疾。然而，坚持以证据为基础的建议具有挑战性，需要在患者、提供者和卫生系统层面进行干预。目的:本研究旨在开发一款智能个体化心血管风险消除应用程序(iCARE)，以促进健康行为和预防药物的依从性，并测试iCARE的可用性。方法:我们基于以用户为中心的设计方法开发了iCARE，包括4个阶段:(1)功能设计，(2)迭代设计，(3)专家检查和原型演练，以及(4)最终用户可用性测试。 The usability testing of iCARE included 2 stages: stage I, which included a task analysis and a usability evaluation (January to March 2019) of the iCARE patient app using the modified Health Information Technology Usability Survey (Health-ITUES); and stage II (June 2020), which used the Health-ITUES among end users who used the app for 6 months. The end users were individuals with a confirmed diagnosis of CHD from 2 university-affiliated hospitals in Beijing, China. Results: iCARE consists of a patient app, a care provider app, and a cloud platform. It has a set of algorithms that trigger tailored feedback and can send individualized interventions based on data from initial assessment and health monitoring via manual entry or wearable devices. For stage I usability testing, 88 hospitalized patients (72{\%} [63/88] male; mean age 60 [SD 9.9] years) with CHD were included in the study. The mean score of the usability testing was 90.1 (interquartile range 83.3-99.0). Among enrolled participants, 90{\%} (79/88) were satisfied with iCARE; 94{\%} (83/88) and 82{\%} (72/88) reported that iCARE was useful and easy to use, respectively. For stage II usability testing, 61 individuals with CHD (85{\%} [52/61] male; mean age 53 [SD 8.2] years) who were from an intervention arm and used iCARE for at least six months were included. The mean total score on usability testing based on the questionnaire was 89.0 (interquartile distance: 77.0-99.5). Among enrolled participants, 89{\%} (54/61) were satisfied with the use of iCARE, 93{\%} (57/61) perceived it as useful, and 70{\%} (43/61) as easy to use. Conclusions: This study developed an intelligent, individualized, evidence-based, and theory-driven app (iCARE) to improve patients' adherence to health behaviors and medication management. iCARE was identified to be highly acceptable, useful, and easy to use among individuals with a diagnosis of CHD. Trial Registration: Chinese Clinical Trial Registry ChiCTR-INR-16010242; https://tinyurl.com/2p8bkrew ", issn="2291-5222", doi="10.2196/26439", url="https://mhealth.www.mybigtv.com/2021/12/e26439", url="https://doi.org/10.2196/26439", url="http://www.ncbi.nlm.nih.gov/pubmed/34898449" }